Please assess the completion status of the following clinical trial:

Trial Title: 3BNC117 and 10-1074 in HIV-infected Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~All groups:~* Age 18 to 65.~* HIV-1 infection confirmed by two independent laboratory assays.~* If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting intrauterine device (IUD), hormone-based contraceptive with condom) for the study duration.~Groups 1A and 1B:~* HIV-infected volunteers on ART with HIV-1 plasma RNA levels \< 20 copies/ml.~* Current CD4 cell count \> 300 cells/μl.~Groups 1C and 3:~* HIV-infected volunteers off ART with detectable HIV-1 plasma RNA levels \< 100,000 copies/ml by standard assays.~* Current CD4 cell count \> 300 cells/μl.~Group 2:~* On antiretroviral therapy for a minimum of 24 months, with plasma HIV-1 RNA levels of \< 50 copies/ml for at least 18 months, and \< 20 copies/ml at screening. Note: a single viral load measurement \> 50 but \< 500 copies/ml during this time period is allowed.~* Current CD4+ T cell counts \> 500 cells/μl. CD4 cell count nadir \> 200 cells/μl.~* If on an NNRTI-based regimen willing to switch to a dolutegravir-based regimen for 4 weeks prior to discontinuing ART.~Exclusion Criteria:~* Have a history of AIDS-defining illness within 3 year prior to enrollment.~* History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.~* Any clinically significant acute or chronic medical condition (such as autoimmune diseases or coronary artery disease), other than HIV infection, that in the opinion of the investigator would preclude participation.~* Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.~* History of resistance to 2 or more classes of antiretroviral medication or known resistance to dolutegravir in participants on non-nucleoside reverse-transcriptase inhibitors (NNRTI), who would switch regimen prior to ATI (Group 2).~* Laboratory abnormalities in the parameters listed below:~* Absolute neutrophil count ≤ 1,000 cells/l~* Hemoglobin ≤ 10 gm/dL~* Platelet count ≤ 100,000 cells/l~* Alanine Aminotransferase (AST) ≥ 1.5 x ULN~* Aspartate Aminotransferase (AST) ≥ 1.5 x ULN~* Alkaline phosphatase ≥ 1.5 x ULN~* Total bilirubin \> 1.0 ULN~* eGFR \< 60 mL/min/1.73m2~* Pregnancy or lactation;~* Any vaccination within 14 days prior to 3BNC117 and 10-1074 administration;~* Subjects with known hypersensitivity to any constituent of the investigational products;~* Receipt of any therapeutic HIV vaccine or monoclonal antibody therapy of any kind in the past;~* Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1A (Type: EXPERIMENTAL): HIV-infected individuals, on ART with HIV-1 RNA \< 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
- Group 1B (Type: EXPERIMENTAL): HIV-infected individuals, on ART with HIV-1 RNA \< 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.
- Group 1C (Type: EXPERIMENTAL): HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.
- Group 2 (Type: EXPERIMENTAL): HIV-infected individuals, on ART with HIV-1 RNA \< 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.
- Group 3 (Type: EXPERIMENTAL): HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete